Becton, Dickinson and Company $BDX Position Lifted by Evelyn Partners Investment Management Europe Ltd

Evelyn Partners Investment Management Europe Ltd grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 1,417.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,017 shares of the medical instruments supplier’s stock after acquiring an additional 950 shares during the period. Evelyn Partners Investment Management Europe Ltd’s holdings in Becton, Dickinson and Company were worth $175,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Becton, Dickinson and Company by 15.4% in the second quarter. Vanguard Group Inc. now owns 32,308,749 shares of the medical instruments supplier’s stock valued at $5,565,182,000 after buying an additional 4,305,947 shares during the last quarter. First Eagle Investment Management LLC grew its position in shares of Becton, Dickinson and Company by 59.2% in the 2nd quarter. First Eagle Investment Management LLC now owns 8,786,190 shares of the medical instruments supplier’s stock worth $1,513,421,000 after acquiring an additional 3,268,478 shares in the last quarter. GQG Partners LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $689,833,000. Massachusetts Financial Services Co. MA raised its position in shares of Becton, Dickinson and Company by 24.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 8,514,446 shares of the medical instruments supplier’s stock valued at $1,466,613,000 after acquiring an additional 1,670,590 shares in the last quarter. Finally, Nuveen LLC bought a new position in Becton, Dickinson and Company during the first quarter worth $211,097,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $192.57 on Friday. The firm’s 50 day moving average is $186.83 and its two-hundred day moving average is $182.21. The firm has a market capitalization of $55.20 billion, a P/E ratio of 34.63, a PEG ratio of 1.42 and a beta of 0.25. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. Analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 31st. Investors of record on Monday, December 8th will be paid a dividend of $1.05 per share. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Analyst Ratings Changes

A number of analysts have weighed in on BDX shares. Stifel Nicolaus dropped their target price on shares of Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Piper Sandler dropped their price objective on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wall Street Zen cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Royal Bank Of Canada cut their price target on Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating on the stock in a report on Friday, November 7th. Three investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $203.27.

Insider Activity

In other news, Director Claire Fraser sold 917 shares of the company’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the transaction, the director owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 1,249 shares of company stock valued at $231,358 in the last ninety days. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.